# US 2022/0249710 A1 · Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0249710 A1
- Document ID: US20220249710A1
- Status: Published application
- Kind: A1
- Application number: 17/725,271
- Filed: 2022-04-20
- Published: 2022-08-11
- Earliest claimed: 2017-09-19
- Assignees: The Governors of the University of Alberta
- Applicants: The Governors of the University of Alberta
- Inventors: Piyush KUMAR; Hassan ELSAIDI; Leonard Irving WIEBE; Michael WEINFELD; Carolynne Lacar RICARDO
- Web page: https://patentgrep.com/patent/US20220249710A1

## CPC

- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 49/10: Organic compounds
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61P 35/00: Antineoplastic agents
- C07D 253/08: condensed with carbocyclic rings or ring systems
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- G01N 33/60: involving radioactive labelled substances
- G21H 5/02: as tracers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G21H: OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION (measurement of nuclear or X-radiation G01T; fusion reactors G21B; nuclear reactors G21C; lamps in which a gas filling is excited to luminescence by external corpuscular radiation or by radioactive material structurally associated with the lamp H01J65/04, H01J65/06)

## Abstract

Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.

## Claims

### Claim 1

A compound of formula (I), or any prodrug, pharmaceutically acceptable salt, metabolite, polymorph, solvate, hydrate, stereoisomer, radioisotope, or tautomer thereof:
wherein BA comprises one or more of 2/4/5-substituted nitroimidazoles, substituted benzotriazene-1,4-dioxides, substituted 1,2,3/1,2,4-triazoles, substituted 1,4-benzoquinones, or combination of two homo- or hetero BA moieties,
wherein Linker Arm is —C1-16 alkane, alkene, alkyne, alicyclic, aromatic with or without hetero atoms as in ethers, amines, esters, acids, amides; 5 and 6 membered rings with the substitutions as described above, both monosaccharides and disaccharides,
wherein the (Radio)theranostic Arm comprises 18/19F, 123/124/125/127/131I, Lu-177, Ga-68, 99mTC, etc.

### Claim 2 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof as a diagnostic agent in a subject.

### Claim 3 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof as a therapeutic agent in a subject.

### Claim 4 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof as a diagnostic and therapeutic agent in a subject.

### Claim 5 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof as an imaging agent in a subject.

### Claim 6 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof as a radiosensitization agent in a subject.

### Claim 7 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof as a chemosensitization agent in a subject.

### Claim 8 (depends on 1)

A method of administering a compound of claim 1 or a radio-labeled compound thereof in the treatment of a hypoxia tumours and/or cancers, diabetes, inflammatory arthritis, anaerobic bacterial infection, stroke, brain trauma or transplant rejection.

### Claim 9 (depends on 2)

The method of claim 2, wherein said subject is a human.
